- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ABIVAX SA ADR Aktie jetzt für 0€ handeln | |||||
| Fr | Citizens JMP bekräftigt "Market Outperform"-Rating für Abivax | 20 | Investing.com Deutsch | ||
| Fr | Abivax stock rating reiterated at Market Outperform by Citizens JMP | 5 | Investing.com | ||
| 14.07. | Citizens JMP reiterates Market Outperform rating on Abivax stock | 33 | Investing.com | ||
| 02.07. | Piper Sandler reiterates Overweight rating on Abivax stock ahead of UC data | 28 | Investing.com | ||
| 11.06. | Abivax Announces Results of its June 6, 2025 Annual General Meeting | 505 | Dow Jones News | DJ Abivax Announces Results of its June 6, 2025 Annual General Meeting
ABIVAX
Abivax Announces Results of its June 6, 2025 Annual General Meeting
11-Jun-2025 / 22:00 CET/CEST
Dissemination of... ► Artikel lesen | |
| 11.06. | EQS-News: ABIVAX: Abivax Announces Results of its June 6, 2025 Annual General Meeting | 438 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its June 6, 2025 Annual General Meeting
11.06.2025 / 22:00 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| 11.06. | Abivax S.A. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 03.06. | Abivax: Höherer Nettoverlust, Cash-Reserve schrumpft schnell | 744 | 4investors | Abivax hat im ersten Quartal 2025 einen Nettoverlust von 52,4 Millionen Euro ausgewiesen, verglichen mit 42,9 Millionen Euro im Vorjahreszeitraum. Der Anstieg resultiert nach Angaben des französischen... ► Artikel lesen | |
| 02.06. | Abivax reports Q1 results | 16 | Seeking Alpha | ||
| 02.06. | Abivax S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.06. | EQS-News: ABIVAX: Abivax Presents First Quarter 2025 Financial Results | 411 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Quarter Results
Abivax Presents First Quarter 2025 Financial Results
02.06.2025 / 22:00 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| 30.04. | JMP maintains $33 target on Abivax stock amid Phase 3 progress | 48 | Investing.com | ||
| 29.04. | EQS-News: ABIVAX: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis | 436 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Study
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis... ► Artikel lesen | |
| 22.04. | Abivax S.A. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 22.04. | Abivax beruft Immunologie-Experten in den Vorstand vor Studienergebnissen | 11 | Investing.com Deutsch | ||
| 22.04. | Abivax adds immunology expert to board ahead of trial results | 2 | Investing.com | ||
| 22.04. | EQS-News: ABIVAX: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones | 550 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
22.04.2025 / 22:05... ► Artikel lesen | |
| 22.04. | EQS-News: ABIVAX: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors | 446 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
22.04.2025 / 22:00 CET/CEST
The issuer is solely... ► Artikel lesen | |
| 26.03. | EQS-News: ABIVAX: Abivax publishes financial reports with the French and U.S. securities regulatory agencies | 443 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Annual Report
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
26.03.2025 / 22:05 CET/CEST
The... ► Artikel lesen | |
| 25.03. | BTIG maintains $43 target on Abivax stock following analyst event | 37 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,200 | -16,85 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| QIAGEN | 41,050 | -0,86 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,540 | +11,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| BIONTECH | 93,70 | -1,00 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 57,00 | +1,79 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| ITEOS THERAPEUTICS | 10,300 | +0,29 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| SAB BIOTHERAPEUTICS | 2,950 | +4,98 % | SAB Biotherapeutics sichert sich 175 Mio. US-Dollar über Privatplatzierung - Aktie legt um 33 % zu | ||
| AVIDITY BIOSCIENCES | 34,920 | +3,50 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,230 | +2,41 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| 180 LIFE SCIENCES | 3,220 | +71,28 % | 180 Life Sciences beschleunigt Zuteilung von Aktienvergütungen für Führungskräfte | ||
| SUMMIT THERAPEUTICS | 26,630 | +1,64 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| REDHILL BIOPHARMA | 2,820 | +46,11 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| ABSCI | 3,570 | +14,24 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
| BRUKER | 30,540 | -12,49 % | Bruker-Aktie bricht nach Umsatzwarnung für Q2 ein | ||
| VERVE THERAPEUTICS | 10,990 | +0,69 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly |
ABIVAX SA ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,100 Euro und damit -1,22 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABIVAX SA ADR finden Sie auf Wallstreet Online.